Meeting
2022 ASCO Quality Care Symposium
Pathologic complete responses and overall survival after neoadjuvant chemotherapy for muscle-invasive bladder cancer: Analyzing the impact of race.
Authors
Arya Mariam Roy
Roswell Park Comprehensive Cancer Center, Buffalo, NY
Arya Mariam Roy, Changchuan Jiang, Stuthi Perimbeti, Karan Jatwani, Gurkamal S. Chatta, Dharmesh Gopalakrishnan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Cost, Value, and Policy,Health Care Access, Equity, and Disparities,Patient Experience
Sub Track
Cancer Outcome Disparities
Citation
J Clin Oncol 40, 2022 (suppl 28; abstr 146)
DOI
10.1200/JCO.2022.40.28_suppl.146
Abstract #
146
Poster Bd #
E15
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
The Bristol Bladder Trial: Five year outcomes in patients treated with neoadjuvant cabazitaxel and cisplatin chemotherapy for muscle invasive transitional cell carcinoma of the urinary bladder.
First Author: Amarnath Challapalli
Poster
2022 ASCO Genitourinary Cancers Symposium
Impact of angiotensin-converting enzyme inhibitors (ACEi) on pathologic complete response with neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC).
First Author: Jonathan Thomas
Poster
2021 ASCO Annual Meeting
Use of neoadjuvant chemotherapy in elderly patients with muscle invasive bladder cancer: A population-based study, 2006 to 2017.
First Author: Natasza Posielski
Poster
2021 Genitourinary Cancers Symposium
Impact of angiotensin inhibitors on pathologic complete response with neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC).
First Author: Jonathan Thomas